Los Angeles, CA — March 19, 2026 — The Terasaki Institute for Biomedical Innovation (TIBI) and UCLA Technology Development Group (TDG) announced today a collaboration to program the Advanced Organ and Tissue Repair session during MedTech Day at LABEST, one of Southern California’s premier innovation conferences.
Los Angeles, CA — March 17, 2026 — The Terasaki Institute for Biomedical Innovation (TIBI) is proud to announce that Principal Investigator Dr. Aliesha O’Raw, Co-Founder of OnVagus, has been selected for the 2026 American Cancer Society (ACS) BrightEdge Entrepreneurs (BEE) Program cohort. The BrightEdge Entrepreneurs Program is a competitive program for startups in the cancer diagnostic and therapeutic space, providing mentorship and entrepreneur training alongside early-stage investment support, including a $100,000 SAFE (Simple Agreement for Future Equity) backed by ACS’ BrightEdge Investment Fund.
Los Angeles, CA – March 9, 2026 – The Terasaki Institute for Biomedical Innovation (TIBI) and Keck Graduate Institute (KGI) have announced a new collaborative research partnership designed to accelerate biomedical innovation through joint research programs, faculty collaboration, and expanded student training opportunities.
Los Angeles, CA – February 23, 2026 - Dr. Vadim Jucaud, Principal Investigator and Assistant Professor at the Terasaki Institute, with Co-Principal Investigator Angeles Baquerizo, MD, PhD, FACS, FAASLD have been awarded an NIH R21 research grant to develop a first-of-its-kind organ-on-a-chip platform to study immune rejection in pig-to-human liver transplantation. The project tackles one of the most pressing challenges in modern transplantation medicine: advancing xenotransplantation toward safe and effective clinical use.
Los Angeles, CA – February 18, 2026 - Dr. Vadim Jucaud’s lab at the Terasaki Institute has developed a vascularized liver tissueoid-on-a-chip (LToC) platform that recapitulates key structural, functional, and immunological features of human liver tissue, enabling the study of liver regeneration and immune-mediated allograft rejection in a physiologically relevant human system.
Los Angeles, CA – January 27, 2026 - The 2026 Summer Internship Program at the Terasaki Institute for Biomedical Innovation (TIBI) is designed as an immersive, hands-on training experience that equips students with the technical, analytical, and creative skills needed for modern bioengineering and translational research.
Los Angeles, CA – January 27, 2026 -The Terasaki Institute is pleased to announce the winners of its 2025 Media Contest, themed “Shaping Life, One Breakthrough at a Time.” This year’s entries celebrated the innovative spirit driving advances in healthcare, capturing moments where discovery, technology, and impact intersect, from lab-bench breakthroughs to real-world applications shaping the future of health and medicine.
Los Angeles, CA – December 22, 2025 -The Terasaki Institute for Biomedical Innovation (TIBI) concludes 2025 with a renewed sense of purpose and momentum. Following a year marked by scientific discoveries, community connections, and institutional resilience, the Institute continued to advance its mission of developing personalized, translational solutions that improve human health. Across cancer biology, regenerative medicine, immunoengineering, biosensing, and global collaboration, TIBI’s researchers, partners, and students demonstrated exceptional dedication to building a healthier future.